Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Video

Updated: Jun 16, 2026

Studying Triple Negative Breast Cancer Using Orthotopic Breast Cancer Model
09:29

Studying Triple Negative Breast Cancer Using Orthotopic Breast Cancer Model

Published on: March 20, 2020

What is the difference between triple-negative and basal breast cancers?

Melanie D Seal1, Stephen K Chia

  • 1Department of Medical Oncology, BC Cancer Agency, University of British Columbia, Vancouver, BC, Canada.

Cancer Journal (Sudbury, Mass.)
|February 19, 2010
PubMed
Summary

Triple-negative breast cancer (TNBC) lacks key receptors, driving research interest. Basal-like breast cancer (BLBC) is a distinct subtype, not synonymous with TNBC, with ongoing research into its diversity.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Clonal Hematopoiesis of Indeterminate Potential and its Association with Treatment Outcomes and Adverse Events in Patients with Solid Tumors.

Cancer research communications·2024
Same author

Breast Cancer Index and Prediction of Extended Aromatase Inhibitor Therapy Benefit in Hormone Receptor-Positive Breast Cancer from the NRG Oncology/NSABP B-42 Trial.

Clinical cancer research : an official journal of the American Association for Cancer Research·2024
Same author

Current Challenges and Disparities in the Delivery of Equitable Breast Cancer Care in Canada.

Current oncology (Toronto, Ont.)·2023
Same author

Ten-year update: NRG Oncology/National Surgical Adjuvant Breast and Bowel Project B-42 randomized trial: extended letrozole therapy in early-stage breast cancer.

Journal of the National Cancer Institute·2023
Same author

Impact of the 21-Gene Recurrence Score Assay on the Treatment of Estrogen Receptor-Positive, HER2-Negative, Breast Cancer Patients With 1-3 Positive Nodes: A Prospective Clinical Utility Study.

Clinical breast cancer·2021
Same author

<i>ESR1</i> Mutations and Overall Survival on Fulvestrant versus Exemestane in Advanced Hormone Receptor-Positive Breast Cancer: A Combined Analysis of the Phase III SoFEA and EFECT Trials.

Clinical cancer research : an official journal of the American Association for Cancer Research·2020

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • Triple-negative breast cancer (TNBC) is defined by the absence of estrogen receptor, progesterone receptor, and HER2 expression.
  • TNBC exhibits aggressive behavior and lacks targeted therapies, making it a critical research focus.
  • Gene expression profiling has identified intrinsic breast cancer subtypes, including basal-like breast cancer (BLBC).

Purpose of the Study:

  • To clarify the biological definition and characteristics of basal-like breast cancer (BLBC).
  • To differentiate BLBC from the broader triple-negative breast cancer (TNBC) phenotype.
  • To review current evidence regarding the diversity within the BLBC subtype.

Main Methods:

  • Literature review of current scientific evidence.

More Related Videos

In Vivo Immunofluorescence Localization for Assessment of Therapeutic and Diagnostic Antibody Biodistribution in Cancer Research
08:53

In Vivo Immunofluorescence Localization for Assessment of Therapeutic and Diagnostic Antibody Biodistribution in Cancer Research

Published on: September 16, 2019

Related Experiment Videos

Last Updated: Jun 16, 2026

Studying Triple Negative Breast Cancer Using Orthotopic Breast Cancer Model
09:29

Studying Triple Negative Breast Cancer Using Orthotopic Breast Cancer Model

Published on: March 20, 2020

In Vivo Immunofluorescence Localization for Assessment of Therapeutic and Diagnostic Antibody Biodistribution in Cancer Research
08:53

In Vivo Immunofluorescence Localization for Assessment of Therapeutic and Diagnostic Antibody Biodistribution in Cancer Research

Published on: September 16, 2019

  • Analysis of gene expression profiling data.
  • Comparison of TNBC and BLBC phenotypes.

    • Main Results:

    • TNBC and BLBC are distinct biological entities, not interchangeable terms.
    • BLBC represents an intrinsic subtype identified through gene expression profiling.
    • Significant heterogeneity exists within the BLBC subtype.

    Conclusions:

    • Basal-like breast cancer (BLBC) is a specific molecular subtype with unique biological characteristics.
    • Distinguishing BLBC from TNBC is crucial for understanding breast cancer biology and developing targeted treatments.
    • Further research is needed to explore the diversity within BLBC for personalized therapeutic strategies.